PTC reports positive Phase II Huntington’s data, FDA lifts partial clinical hold
PTC reports positive Phase II Huntington’s data, FDA lifts partial clinical hold
PTC reports positive Phase II Huntington’s data, FDA lifts partial clinical hold
Published: Jun 20, 2024
By Tyler Patchen
BioSpace
PTC Therapeutics announced Thursday that its Huntington’s disease candidate PTC518 is no longer subject to an FDA partial clinical hold after it showed positive interim results from a Phase II study.
Interim results from the PIVOT-HD trial of PTC518 in Huntington’s disease (HD) patients demonstrated the oral small molecule lowered mutant huntingtin (mHTT) protein levels in the blood and cerebrospinal fluid (CSF). PTC also touted “favorable trends” shown on several HD clinical assessments, including Total Motor Score and Composite Unified Huntington’s Disease Rating Scale. The candidate was also found to be safe and well-tolerated after 12 months of treatment.
PTC518 lowered mHTT levels in the blood by 22% and 43% at the 5mg and 10mg doses, respectively. For the CSF metric, dose-dependent mHTT was reduced by 21% at the 5mg dose and 43% at the 10mg dosage. In slowing the progression of motor symptoms, a worsening by 2.0 points at the 5mg dosage amount was recorded, while a 1.3 point worsening was found at the 10mg level. By comparison, patients taking the placebo had a worsening of 4.9 points.
“The evidence of both CNS biomarker and early clinical effects at month 12 along with the continued favorable tolerability profile supports the promise of PTC518 to address the need for an effective and safe disease-modifying therapy for patients living with Huntington’s disease,” PTC CEO Matthew Klein said in a statement.
PTC reported that the FDA lifted its partial clinical hold on the candidate based on a data review. In October 2022, the FDA put the program on pause after the agency requested more data to support PTC518’s dosing and duration proposed in the 12-month study, the company told BioSpace at the time. However, PTC continued to enroll patients in other locations worldwide.
Thursday’s positive results for PTC come as other players in the Huntington’s space continue to struggle. Earlier this month, Sage Therapeutics announced that its oral NMDA receptor dalzanemdor had a slight numerical improvement in a Phase II Huntington’s trial. However, no data were provided and in a note to investors William Blair analysts said that the results were “underwhelming” and they remain cautious about Sage’s candidate as the small changes are not seen as “definitive.”
Tyler Patchen is a staff writer at BioSpace. You can reach him at [email protected]. Follow him on LinkedIn.
Source: BioSpace
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: